2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.074 Jens Samol NACLC23 Abstract

PP01.074 Jens Samol NACLC23 Abstract

Pdf Summary

A prospective multicenter study compared the performance of LiquidHALLMARK and Guardant360 liquid biopsies in detecting guideline-recommended biomarkers for non-squamous non-small-cell lung cancer (NSCLC). LiquidHALLMARK ctDNA is an amplicon-based next-generation sequencing (NGS) liquid biopsy that detects alterations in 80 genes, while Guardant360 is a hybrid-capture-based ctDNA test approved by the FDA. The study enrolled 151 patients from the US and Singapore and evaluated the detection of G9 biomarkers, including EGFR, ALK, ROS1, RET, BRAF V600E, MET, KRAS G12C, ERBB2/HER2, and NTRK1/2/3 genes, as well as fusion detection using ctRNA.<br /><br />The results showed that LiquidHALLMARK-ctDNA demonstrated concordance of 93.2-100% with tissue NGS for all G9 biomarkers. In comparison to tissue NGS, LiquidHALLMARK-ctDNA detected 15.6% more G9 biomarkers than Guardant360 in patients with tissue-confirmed G9 biomarkers. Furthermore, in patients with available ctRNA reports, LiquidHALLMARK-ctRNA detected 20% more G9 biomarkers compared to ctDNA-only testing. LiquidHALLMARK-ctDNA identified 6 guideline-recommended fusions, while LiquidHALLMARK-ctRNA detected 7 fusions. Two additional guideline-recommended fusions were detected only on ctRNA testing, which were missed on ctDNA-only testing.<br /><br />The study concluded that LiquidHALLMARK-ctDNA testing detected more tissue-confirmed guideline-recommended biomarkers than Guardant360-ctDNA testing. Additionally, the study provided evidence of the clinical utility of ctRNA in identifying guideline-recommended biomarkers for therapy selection in NSCLC. LiquidHALLMARK, with its comprehensive approach and fusion detection capability, could be a valuable tool for selecting targeted therapies for patients with metastatic NSCLC. The findings highlight the importance of liquid biopsies in non-invasive biomarker detection and personalized medicine for lung cancer patients.

Keywords

LiquidHALLMARK

Guardant360

liquid biopsies

NSCLC

amplicon-based sequencing

hybrid-capture-based ctDNA

G9 biomarkers

fusion detection

ctRNA

tissue NGS